Abivax SA ADS/$ABVX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Abivax SA ADS
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. The company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD. The Group operates in a single operating segment: R&D of pharmaceutical products in order to market them in the future.
Ticker
$ABVX
Sector
Primary listing
Employees
80
Headquarters
Website
Abivax SA ADS Metrics
BasicAdvanced
$12bn
-
-$5.17
-0.20
-
Price and volume
Market cap
$12bn
Beta
-0.2
52-week high
$148.83
52-week low
$7.70
Average daily volume
3.2m
Financial strength
Current ratio
8.247
Quick ratio
8.072
Long term debt to equity
7.707
Total debt to equity
7.964
Interest coverage (TTM)
-9.63%
Profitability
EBITDA (TTM)
-290.022
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-6,752.03%
Operating margin (TTM)
-5,184.63%
Effective tax rate (TTM)
-1.86%
Revenue per employee (TTM)
$68,500
Management effectiveness
Return on assets (TTM)
-44.65%
Return on equity (TTM)
-157.07%
Valuation
Price to revenue (TTM)
1,858.167
Price to book
23.4
Price to tangible book (TTM)
24.85
Price to free cash flow (TTM)
-51.21
Free cash flow yield (TTM)
-1.95%
Free cash flow per share (TTM)
-2.776
Growth
Revenue change (TTM)
-59.82%
Earnings per share change (TTM)
53.85%
3-year revenue growth (CAGR)
3.13%
10-year revenue growth (CAGR)
42.60%
3-year earnings per share growth (CAGR)
12.38%
10-year earnings per share growth (CAGR)
10.22%
Abivax SA ADS News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs